Compare AVLN & CWH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVLN | CWH |
|---|---|---|
| Founded | N/A | 1966 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2026 | 2016 |
| Metric | AVLN | CWH |
|---|---|---|
| Price | $29.23 | $6.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.78 |
| AVG Volume (30 Days) | 545.5K | ★ 2.0M |
| Earning Date | N/A | 04-29-2026 |
| Dividend Yield | N/A | ★ 5.41% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 3.99 |
| Revenue | N/A | ★ $4,792,017,000.00 |
| Revenue This Year | N/A | $4.63 |
| Revenue Next Year | N/A | $5.72 |
| P/E Ratio | ★ N/A | $1.59 |
| Revenue Growth | N/A | ★ 11.83 |
| 52 Week Low | $27.33 | $5.70 |
| 52 Week High | $33.32 | $19.38 |
| Indicator | AVLN | CWH |
|---|---|---|
| Relative Strength Index (RSI) | 35.88 | 40.27 |
| Support Level | $27.37 | $6.15 |
| Resistance Level | $33.32 | $8.31 |
| Average True Range (ATR) | 2.54 | 0.47 |
| MACD | -0.26 | -0.14 |
| Stochastic Oscillator | 31.72 | 12.09 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Camping World Holdings Inc is a retailer of RVs and related products and services. The company has two reportable segments; the Good Sam Services and Plans segment, which includes the sale of emergency roadside assistance plans; commissions on property and casualty insurance programs; travel assist programs; extended vehicle service contracts; vehicle financing and refinancing assistance; consumer shows and events; and consumer publications and directories; and the RV and Outdoor Retail segment, which generates maximum revenue and includes the sale of new and used RVs; commissions on the finance and insurance contracts related to the sale of RVs; the sale of RV service and collision work; the sale of RV parts, accessories, business to business distribution of RV furniture, etc.